Abstract: Rosuvastatin is a newer HMG-CoA reductase inhibitor which shows some specific pharmacological and pharmacokinetic properties. Rosuvastatin claimed as a “super-statin” which decreases the LDL cholesterol comparing to other statins. A benefit-risk profile of Rosuvastatin makes it more sustanable to treat dyslipidemia. Rosuvastatin plays an important role in the various cardiovascular diseases. Rosuvastatin is cholesterol lowering agent which is used in the treatment of various cardiovascular diseases, cerebrovascular and peripheral vascular diseases. It is favorable balance including anti-inflammatory and antioxidant effects and improvement in endothelial dysfunction, are related with slowing of progress of dyslipidemia within the artery wall. In combination of other statins, rosuvastatin did not show benefit in terms of survival in patients with cardiac heart failure. those patients at end-stage renal disease undergoing chronic hemodialysis, rosuvastatin has no effect on decreasing cardiovascular events. There is a moderately elevated risk of incident of diabetes with this class of agents. Rosuvastatin is an appropriate medication therapy in addition to antihypertensive treatment to decrease cardiovascular risk in hypertensive patients with other statins. Rosuvastatin have less extrahepatic tissue penetration, low potential for CYP3A4 interactions and substantial LDL-C lowering capacity, therefore it has distinct benifits. This review outlines the pharmacology of rosuvastatin, highlighting its efficacy and safety and overview on the analytical methods of rosuvastatin in pharmaceutical dosage form.
